Protagonist Therapeutics Inc reports results for the quarter ended in September 30 - Earnings Summary

Protagonist Therapeutics

08/11/2024 04:55

* Protagonist Therapeutics Inc  PTGX.OQ  reported a
quarterly
adjusted loss of 54 cents​​ per share for the quarter ended
September 30, higher than the same quarter last year, when the
company reported EPS of -58 cents.  The mean expectation of
eight analysts for the quarter was for a loss of 61 cents per
share. Wall Street expected results to range from -71 cents
to -45 cents per share.
    * Revenue was $4.68 million​; analysts expected $2.07
million. 
    * Protagonist Therapeutics Inc's reported EPS for the
quarter was
a loss of 54 cents​.
    * The company reported a quarterly loss of $33.21 million.
    * Protagonist Therapeutics Inc shares had risen by 5.8% this
quarter and gained 107.6% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 3.3%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Protagonist
Therapeutics Inc is 52.00 
This summary was machine generated from LSEG data November 8 at
04:54 a.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      -0.61          -0.54          Beat
 Jun. 30 2024      -0.60          -0.50          Beat
 Mar. 31 2024      1.19           3.26           Beat
 Dec. 31 2023      -0.03          0.44           Beat